Alzamend Neuro (ALZN) 10-K 27 Jul 23 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Apr. 30, 2023	Jul. 24, 2023	Oct. 31, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Apr. 30, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--04-30
Entity File Number	001-40483
Entity Registrant Name	ALZAMEND NEURO, INC.
Entity Central Index Key	0001677077
Entity Tax Identification Number	81-1822909
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	3480 Peachtree Road NE
Entity Address, Address Line Two	Second Floor Suite 103
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30326
City Area Code	(844)
Local Phone Number	722-6333
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	ALZN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 66,400,000
Entity Common Stock, Shares Outstanding		96,940,124
Documents Incorporated by Reference [Text Block]	None
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	23
Auditor Name	BAKER TILLY US, LLP
Auditor Location	San Diego, California

Balance Sheets

Balance Sheets - USD ($)	Apr. 30, 2023	Apr. 30, 2022
CURRENT ASSETS
Cash	$ 5,140,859	$ 14,063,811
Prepaid expenses and other current assets	447,589	349,723
Prepaid expenses - related party	247,334
TOTAL CURRENT ASSETS	5,835,782	14,413,534
Property, plant and equipment, net	79,843	102,909
TOTAL ASSETS	5,915,625	14,516,443
CURRENT LIABILITIES
Accounts payable and accrued liabilities	2,870,122	1,162,850
Related party payable		2,082
TOTAL CURRENT LIABILITIES	2,870,122	1,164,932
TOTAL LIABILITIES	2,870,122	1,164,932
STOCKHOLDERS’ EQUITY
Convertible Preferred stock, $0.0001 par value: 10,000,000 shares authorized; Series A Convertible Preferred Stock, $0.0001 stated value per share, 1,360,000 shares designated; nil 0 issued and outstanding as of April 30, 2023 and 2022
Common stock, $0.0001 par value: 300,000,000 shares authorized; 96,940,124 and 95,481,790 shares issued and outstanding as of April 30, 2023 and 2022, respectively	9,694	9,548
Additional paid-in capital	61,991,766	57,419,753
Note receivable for common stock – related party	(14,883,295)	(14,883,295)
Accumulated deficit	(44,072,662)	(29,194,495)
TOTAL STOCKHOLDERS’ EQUITY	3,045,503	13,351,511
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 5,915,625	$ 14,516,443

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Apr. 30, 2023	Apr. 30, 2022
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	96,940,124	95,481,790
Common stock, shares outstanding	96,940,124	95,481,790
Series A Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	8,640,000
Preferred stock shares designated	1,360,000	1,360,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
OPERATING EXPENSES
Research and development	$ 7,445,857	$ 5,201,314
General and administrative	7,424,609	7,118,221
Total operating expenses	14,870,466	12,319,535
Loss from operations	(14,870,466)	(12,319,535)
OTHER INCOME (EXPENSE), NET
Interest expense	(7,701)	(46,524)
Gain on extinguishment of debt		4,000
Total other income (expense), net	(7,701)	(42,524)
NET LOSS	$ (14,878,167)	$ (12,362,059)
Basic net loss per common share	$ (0.15)	$ (0.14)
Diluted net loss per common share	$ (0.15)	$ (0.14)
Basic weighted average common shares outstanding	97,519,016	89,095,274
Diluted weighted average common shares outstanding	97,519,016	89,095,274

Statements of Changes in Stockh

Statements of Changes in Stockholders' Equity - USD ($)	Series A Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Note Recievable For Common Stock Related Party [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Apr. 30, 2021	$ 75	$ 6,743	$ 33,721,860	$ (14,883,295)	$ (16,832,436)	$ 2,012,947
Beginning balance, shares at Apr. 30, 2021	750,000	67,429,525
Issuance of common stock for restricted stock awards		$ 42	(42)
Issuance of common stock for restricted stock awards, shares		425,000
Stock-based compensation to employees and consultants			4,408,569			4,408,569
Proceeds from sale of common stocks & warrants-related party		$ 400	5,999,600			6,000,000
Proceeds from sale of common stocks and warrants-related party, shares		4,000,000
Proceeds from stock option exercise		$ 550	1,650			2,200
Proceeds from stock option exercise, shares		5,500,000
Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million		$ 288	12,911,168			12,911,456
Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million, shares		2,875,000
Issuance of shares of common stock for conversion of debt		$ 25	378,373			378,398
Issuance of shares of common stock for conversion of debt, shares		252,265
Conversion of Series A convertible stock	$ (75)	$ 1,500	(1,425)
Conversion of Series A convertible stock, shares	(750,000)	15,000,000
Net loss					(12,362,059)	(12,362,059)
Ending balance, value at Apr. 30, 2022		$ 9,548	57,419,753	(14,883,295)	(29,194,495)	13,351,511
Ending balance, shares at Apr. 30, 2022		95,481,790
Issuance of common stock for restricted stock awards		$ 3	(3)
Issuance of common stock for restricted stock awards, shares		25,000
Stock-based compensation to employees and consultants			3,582,625			3,582,625
Proceeds from stock option exercise		$ 50	150			200
Proceeds from stock option exercise, shares		500,000
Issuance of common stock for related party payable		$ 93	989,241			989,334
Issuance of common stock for related party payable, shares		933,334
Net loss					(14,878,167)	(14,878,167)
Ending balance, value at Apr. 30, 2023		$ 9,694	$ 61,991,766	$ (14,883,295)	$ (44,072,662)	$ 3,045,503
Ending balance, shares at Apr. 30, 2023		96,940,124

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Cash flows from operating activities:
Net loss	$ (14,878,167)	$ (12,362,059)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	23,066	3,549
Interest expense - debt discount		12,770
Gain on extinguishment of debt		(4,000)
Stock-based compensation to employees and consultants	3,582,625	4,408,569
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(97,866)	633,597
Prepaid expenses - related party	739,918
Accounts payable and accrued liabilities	1,707,272	693,584
Net cash used in operating activities	(8,923,152)	(6,613,990)
Cash flows from investing activities:
Purchase of machinery		(106,458)
Net cash used in investing activities		(106,458)
Cash flows from financing activities:
Proceeds from the issuance of common stock and warrants - related party, net		6,000,000
Proceeds from stock option exercise	200	2,200
Payments of related party payable		(58,667)
Proceeds from initial public offering, net of underwriters’ discounts and commissions and issuance costs		12,911,456
Net cash provided by financing activities	200	18,854,989
Net (decrease) increase in cash	(8,922,952)	12,134,541
Cash at beginning of period	14,063,811	1,929,270
Cash at end of period	5,140,859	14,063,811
Non-cash financing activities:
Fair value of warrants issued in connection with March 2021 securities purchase agreement, related party		5,374,509
Conversion of Series A Convertible Preferred Stock		1,425
Issuance of common stock on conversion of note		378,398
Fair value of warrants issued in connection with initial public offering		194,490
Issuance of common stock for related party payable	$ 989,334

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Apr. 30, 2023
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS	1. DESCRIPTION OF BUSINESS Alzamend Neuro, Inc. (the “Company” or “Alzamend”), is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder and post-traumatic stress disorder. With two current product candidates, Alzamend aims to bring treatments or cures to market at a reasonable cost as quickly as possible. The Company’s current pipeline consists of two novel therapeutic drug candidates: (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor (the “Licensor”); and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as ALZN002, through a royalty-bearing exclusive worldwide license from the same Licensor. The Company is devoting substantially all its efforts towards research and development of its two product candidates and raising capital. The Company has not generated any product revenue to date. The Company has financed its operations to date primarily through debt financings and through the sale of its common stock, par value $ 0.0001

LIQUIDITY, GOING CONCERN AND MA

LIQUIDITY, GOING CONCERN AND MANAGEMENT’S PLANS	12 Months Ended
	Apr. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY, GOING CONCERN AND MANAGEMENT’S PLANS	2. LIQUIDITY, GOING CONCERN AND MANAGEMENT’S PLANS The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern. As of April 30, 2023, the Company had cash of $ 5.1 44.1 14.9 8.9 14.1 29.2 In March of 2021, the Company entered into a securities purchase agreement (the “SPA”) with Ault Lending, LLC, formerly Digital Power Lending, LLC (“AL”) and a wholly owned subsidiary of Ault Alliance, Inc. (“AULT”), a related party, pursuant to which the Company sold an aggregate of 6,666,667 10 1.50 3,333,333 3.00 The Company believes its current cash on hand is not sufficient to fund its planned operations through one year after the date the financial statements are issued. These factors create substantial doubt about the Company’s ability to continue as a going concern for at least one year after the date that these audited financial statements are issued. The Company’s inability to continue as a going concern could have a negative impact on the company, including our ability to obtain needed financing. The Company’s financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should it be unable to continue as a going concern. In order to continue as a going concern, the Company will need to raise additional funds. The Company plans to seek additional funding through public equity, private equity and debt financings. Additional funds may also be received from the exercise of warrants (Note 8) and the receipt of funds from the note receivable (Note 4). The terms of any additional financing may adversely affect the holdings or rights of the Company’s stockholders. If the Company is unable to obtain funding, it could be required to delay, reduce or eliminate research and development programs and planned clinical trials which could adversely affect the Company’s business operations.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Apr. 30, 2023
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	3. SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”). Accounting Estimates The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include research and development, stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of April 30, 2023 and 2022, the Company had no Fair Value of Financial Instruments Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase common stock. The fair values of warrants issued in connection with equity or debt issuance are determined using the Black-Scholes valuation model, a “Level 3” fair value measurement, based on the estimated fair value of the underlying common stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants and the risk free interest rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the warrants’ contractual life. Income Taxes The Company determines its income taxes under the asset and liability method. Under the asset and liability approach, deferred income tax assets and liabilities are calculated and recorded based upon the future tax consequences of temporary differences by applying enacted statutory tax rates applicable to future periods for differences between the financial statements carrying amounts and the tax basis of existing assets and liabilities. Generally, deferred income taxes are classified as current or non-current in accordance with the classification of the related asset or liability. Those not related to an asset or a liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are provided for significant deferred income tax assets when it is more likely than not that some or all of the deferred tax assets will not be realized. As of April 30, 2023, the Company had fully reserved the net deferred income tax assets by taking a full valuation allowance against these assets. The Company recognizes tax liabilities by prescribing a minimum probability threshold that a tax position must meet before a financial statement benefit is recognized and also provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The minimum threshold is defined as a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. To the extent that the final tax outcome of these matters is different than the amount recorded, such differences impact income tax expense in the period in which such determination is made. Interest and penalties, if any, related to accrued liabilities for potential tax assessments are included in income tax expense. U.S. GAAP also requires management to evaluate tax positions taken by the Company and recognize a liability if the Company has taken uncertain tax positions that more likely than not would not be sustained upon examination by applicable taxing authorities. Management of the Company has evaluated tax positions taken by the Company and has concluded that as of April 30, 2023, there were no uncertain tax positions taken, or expected to be taken, that would require recognition of a liability that would require disclosure in the financial statements. Research and Development Expenses Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid to clinical research organizations that conduct certain research and development activities on behalf of the Company. The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire licenses, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects. Stock-Based Compensation The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and accounts for forfeitures as they occur. The Company’s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the satisfaction of the performance conditions as of the reporting date. The Company recognizes stock-based compensation expense for restricted stock on a straight-line basis over the requisite service period and accounts for forfeitures as they occur. The Company’s stock-based compensation for restricted stock is based upon the estimated fair value of the Company’s common stock on the date of grant. The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally requires significant judgment. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, the Company’s stock-based compensation could be materially different. Warrants The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging , During the year ended April 30, 2023, based on the terms of the Company’s warrant agreements, the Company accounted for the warrants as equity instruments as the warrants were indexed to the common stock, required settlement in shares and would be classified as equity under ASC 815. Loss per Common Share The Company utilizes FASB ASC Topic No. 260, Earnings per Share Since the effects of outstanding options, restricted stock units and warrants are anti-dilutive in the periods presented, shares of common stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of common stock underlying outstanding options and warrants that have been excluded from the computation of loss per common share: Schedule of antidilutive securities excluded from computation of earnings per share For the Year Ended April 30, 2023 2022 Stock options (1) 18,158,329 18,600,000 Restricted stock units 50,000 75,000 Warrants 10,149,788 10,149,788 28,358,117 28,824,788 (1) The Company has excluded 1,500,000 and 2,000,000 stock options for the years ended April 30, 2023 and 2022, respectively, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.

NOTE RECEIVABLE, RELATED PARTY,

NOTE RECEIVABLE, RELATED PARTY, NET	12 Months Ended
	Apr. 30, 2023
Note Receivable Related Party Net
NOTE RECEIVABLE, RELATED PARTY, NET	4. NOTE RECEIVABLE, RELATED PARTY, NET On April 30, 2019, the Company and Ault Life Science Fund, LLC (“ALSF”), a related party, entered into a securities purchase agreement for the purchase of 10,000,000 15,000,000 1.50 5,000,000 5 3.00 14,883,295

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	12 Months Ended
	Apr. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	5. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets are as follows: Schedule of prepaid expenses and other current assets April 30, 2023 April 30, 2022 Prepaid clinical trial fees $ 352,635 $ - Prepaid insurance 92,154 155,880 Other prepaid expenses 2,800 7,176 Prepaid consulting fees - 186,667 Total prepaid expenses and other current assets $ 447,589 $ 349,723 During the year ended April 30, 2023, the Company prepaid $ 936,000 492,000

INCOME TAXES

INCOME TAXES	12 Months Ended
	Apr. 30, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	6. INCOME TAXES The following is a geographical breakdown of the Company’s loss before the provision for income taxes: Schedule of Income before income tax, domestic and foreign April 30, 2023 April 30, 2022 Pre-tax loss: Federal $ (14,878,167 ) $ (12,362,059 ) Foreign - - Total pre-tax loss $ (14,878,167 ) $ (12,362,059 ) Significant components of the Company’s deferred tax assets were as follows: Schedule of deferred tax assets and liabilities April 30, 2023 April 30, 2022 Deferred income tax asset: Accruals $ 241,500 $ - Capitalized research expenditures 1,426,779 - Net operating loss carryover 6,885,428 8,376,539 Stock compensation 2,276,109 1,722,003 Total deferred tax asset 10,829,816 10,098,542 Fixed assets (16,767 ) (21,611 ) Valuation allowance (10,813,049 ) (10,076,931 ) Deferred income tax asset, net of allowance $ - $ - A reconciliation of the federal statutory income tax rate to the Company’s effective income tax rate for the years ended April 30, 2023 and 2022, is as follows: Schedule of effective income tax rate reconciliation 2023 2022 Tax benefit at U.S. Federal statutory tax rate 21.0 % 21.0 % State income tax, net of federal benefit -18.3 % 12.3 % Increase (decrease) in tax rate resulting from: Change in valuation allowance -4.8 % -46.3 % Stock compensation 0.3 % 13.0 % Other 2.0 % -0.0 % Effective tax rate 0.0 % 0.0 % In assessing the realization of deferred tax assets, management considers whether it is more likely than not the Company’s deferred tax assets will be realized. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making such assessments. Given historical generation of and expected future taxable losses, the Company determined it is more likely than not that some or all of the deferred tax assets will not be realized. Therefore, a full valuation allowance was maintained, as of the years ended April 30, 2023 and 2022, of $ 10,813,049 10,076,931 At April 30, 2023, the Company maintained U.S. Federal and state net operating loss (“NOL”) carryovers of approximately $ 32,787,753 11,419,279 The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. The Company had no The Company’s policy is to recognize interest and penalties related to income tax matters in the provision for income taxes. As of April 30, 2023, no The Company is subject to taxation in the United States and various U.S. state jurisdictions. All tax years remain open to examination by the Internal Revenue Service and relevant state authorities. On December 27, 2020, the Consolidated Appropriations Act, 2021 (“CAA 2021”), which included a number of provisions including, but not limited to, the extension of numerous employment tax credits, the extension of the Section 179D deduction, enhanced business meals deductions, and the deductibility of expenses paid with Paycheck Protection Program loan funds that are forgiven, was signed into law. Accordingly, the effects of the CAA 2021 have been incorporated into the income tax provision for the year ended April 30, 2023. These provisions did not have a material impact on the income tax provision.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Apr. 30, 2023
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	7. STOCK-BASED COMPENSATION 2016 Stock Incentive Plan On April 30, 2016, the Company’s stockholders approved the Company’s 2016 Stock Incentive Plan (the “Plan”). The Plan provides for the issuance of a maximum of 12,500,000 7,500,000 10 2021 Stock Incentive Plan In February 2021, the Company’s board of directors (the “Board”) adopted, and the stockholders approved, the Alzamend Neuro, Inc. 2021 Stock Incentive Plan (the “2021 Plan”). The 2021 Plan authorizes the grant to eligible individuals of (1) stock options (incentive and non-statutory), (2) restricted stock, (3) stock appreciation rights, or SARs, (4) restricted stock units, and (5) other stock-based compensation. Stock Subject to the 2021 Plan. Restricted Stock. Stock Options. A summary of stock option activity for the year ended April 30, 2023, is presented below: Schedule of share-based payment arrangement, option, activity Outstanding Options Shares Number of Weighted Weighted Aggregate Balance at April 30, 2022 8,800,000 15,700,000 $ 1.2154 6.10 $ 2,219,700 Options granted (2,000,000 ) 2,000,000 $ 1.1700 9.58 Options exercised - (500,000 ) $ 0.0004 Options cancelled/forfeited 2,391,671 (2,391,671 ) $ 1.3415 Balance at April 30, 2023 9,191,671 14,808,329 $ 1.2154 6.18 $ 819,900 Options vested and expected to vest at April 30, 2023 13,808,329 $ 1.2187 5.93 $ 819,900 Options exercisable at April 30, 2023 13,036,969 $ 1.1784 5.82 $ 995,400 The aggregate intrinsic value in the table above represents the total pretax intrinsic value (i.e., the difference between the estimated fair value on the respective date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised their options. Stock Options Granted to Employees and Consultants The estimated fair value of stock options granted to employees and consultants during the years ended April 30, 2023 and 2022 were calculated using the Black-Scholes option-pricing model using the following assumptions: Schedule of stock options granted to employees and consultants For the Year Ended April 30, 2023 2022 Expected term (in years) 6.25 6.25 Volatility 88.94% 88.94% Risk-free interest rate 3.89% 2.20% Dividend yield 0.0% 0.0% Expected Term: Expected Volatility: Risk-Free Interest Rate: Expected Dividend: For the year ended April 20, 2023, stock-based compensation related to restricted stock grants and stock options were $63,000 and $3.5 million, respectively, for employees and directors. Performance Contingent Stock Options Granted to Employee On November 26, 2019, the Board granted 4,250,000 In the event any of the stock price milestones are not achieved within three years, the unvested portion of the performance options will be reduced by 25%. On November 22, 2022, the Compensation Committee of the Board modified the performance criteria for these awards. The target price range is now $10 per share to $20 per share. Additionally, if the stock price milestones are now not achieved by November 27, 2026, as opposed to within three years, the unvested portion of the portion of the performance options will be reduced by 25%. Due to the significant risks and uncertainties associated with achieving the market-contingent awards, as of April 30, 2023, the Company believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards. On November 29, 2022, the Compensation Committee of the Board granted 2,000,000 performance-based stock option to the Chief Executive Officer at an exercise price of $1.17 per share, of which 50% vest upon the completion and announcement of topline data from the Company’s Phase II clinical trial of AL001 within three years from grant date and the remaining 50% vest upon the completion and announcement of topline data from the Company’s Phase II clinical trial of ALZN002 within four years from the grant date. As of April 30, 2023, the Company believes that it is probable that the performance condition of the completion and announcement of topline data from the Company’s Phase II clinical trial of AL001 will be achieved and has recognized the related stock-based compensation. As of April 30, 2023, the Company believes that the achievement of the second performance condition is not probable and, as a result, no compensation cost has been recognized related to Phase II of ALZN002. Performance Contingent Stock Options Granted to TAMM Net On March 23, 2021, the Company issued performance-based stock options to the certain team members at TAMM Net, Inc. (“TAMM Net”) to purchase an aggregate of 450,000 The performance goal of completing Phase I of AL001 was achieved on March 22, 2022, and the Company recognized stock-based compensation related to the completion of Phase I of AL001 over the implied service period to complete this milestone. On January 19, 2023, the Board modified the performance criteria for these awards. The remaining 50% of the grant will now vest upon the completion and announcement of topline data of the first cohort from a Phase I/IIA clinical trial of ALZN002 on/or before March 31, 2024. Due to the significant risks and uncertainties associated with achieving the completion of Phase I for ALZN002, as of April 30, 2023, the Company believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards related to ALZN002. Performance Contingent Stock Options Granted to Consultants On October 14, 2021, the Company issued performance-based stock options to two consultants to purchase an aggregate of 200,000 On January 19, 2023, the Board modified the performance criteria for these awards. The revised grant will vest 25% if the Company (a) completes and announces topline data from a Phase II clinical trial of AL001 and ALZN002, as applicable, that would support a new drug application for the drug candidate and the indication listed below, and (b) obtained a “Study May Proceed” letter from the U.S. Food and Drug Administration (“FDA”) for the additional Investigational New Drug (“IND”) on/or before December 31, 2023, as follows: (i) AL001 – bipolar disorder; (ii) AL001- major depressive disorder; (iii) AL001 – post-traumatic stress disorder; and (iv) ALZN002 – Alzheimer’s disease. As of April 30, 2023, the Company believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards related to Phase II of AL001 and ALZN002. Stock-Based Compensation Expense The Company’s results of operations include expenses relating to stock-based compensation for the years ended April 30, 2023 and 2022, were comprised as follows: Schedule of stock-based compensation For the Year Ended April 30, 2023 2022 Research and development $ (42,589 ) $ 423,167 General and administrative 3,625,214 3,985,402 Total $ 3,582,625 $ 4,408,569 As of April 30, 2023, total unamortized stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $ 1.2 1.6

WARRANTS

WARRANTS	12 Months Ended
	Apr. 30, 2023
Warrants
WARRANTS	8. WARRANTS Warrant Issuances During 2022 During the year ended April 30, 2022, the Company issued warrants to purchase an aggregate of 2,000,000 3.00 61,250 6.25 (i) On June 17, 2021, the Company issued a warrant to purchase an aggregate of 61,250 6.25 (ii) On July 28, 2021, the Company received from the FDA a “Study May Proceed” letter for a Phase I study under the Company’s IND application for AL001. Based on the achievement of this milestone, the Company sold an additional 1,333,333 2 1.50 666,667 3.00 (iii) On March 28, 2022, the Company received the full data set from the Phase I clinical trial for AL001. Based on the achievement of this milestone, on April 28, 2022, under the SPA, the Company sold an additional 2,666,667 4 1.50 1,333,333 3.00 The following table summarizes information about common stock warrants outstanding at April 30, 2023 Schedule of common stock warrants outstanding Outstanding Exercisable Weighted Average Weighted Weighted Remaining Average Average Exercise Number Contractual Exercise Number Exercise Price Outstanding Life (years) Price Exercisable Price $ 1.00 500,000 0.8 $ 1.00 500,000 $ 1.00 $ 1.75 161,342 1.5 $ 1.75 161,342 $ 1.75 $ 3.00 9,427,196 1.9 $ 3.00 9,427,196 $ 3.00 $ 6.25 61,250 3.1 $ 6.25 61,250 $ 6.25 $ 1.00 6.25 10,149,788 1.9 $ 2.90 10,149,788 $ 2.90 The estimated fair value of warrants granted during the years ended April 30, 2022, were calculated using the Black-Scholes option-pricing model using the following assumptions: Schedule of assumptions used For the year ended April 30, 2022 Expected term (in years) 5.00 Volatility 88.94% Risk-free interest rate 2.92% Dividend yield 0.0% Expected Term: Expected Volatility: Risk-Free Interest Rate: Expected Dividend:

OTHER RELATED PARTY TRANSACTION

OTHER RELATED PARTY TRANSACTIONS	12 Months Ended
	Apr. 30, 2023
Related Party Transactions [Abstract]
OTHER RELATED PARTY TRANSACTIONS	9. OTHER RELATED PARTY TRANSACTIONS In March of 2021, the Company entered into the SPA with AL pursuant to which the Company sold an aggregate of 6,666,667 10 In addition, the Company issued AL warrants to purchase an aggregate of 3,333,333 shares of common stock at an exercise price of $3.00 per share. Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $ 4 In May 2021, the Board and Mr. Ault, the Company’s Founder and Chairman Emeritus, agreed to certain arrangements with regard to Board composition and other matters. Contemporaneously with the effectiveness of the IPO, and in consideration for (i) the conversion of 750,000 shares of the Company’s Series A Preferred Shares beneficially owned by Mr. Ault through Ault Life Sciences, Inc. into 15,000,000 shares of common stock; (ii) the extension of the maturity date of the note in the original principal amount of $15,000,000 issued to the Company by ALSF, an entity controlled by Mr. Ault, to December 31, 2023; and (iii) the resignation by Mr. Ault as a director and executive officer of the Company 5% 50,000 50,000 88,000 On June 15, 2021, AL, a related party, purchased 2,000,000 5.00 In November 2022, the Company entered into a marketing and brand development agreement with AULT, effective August 1, 2022, whereby AULT will provide various marketing services over twelve months valued at $1.4 million. The Company had the right to pay the fee in cash or shares of its common stock with a value of $1.50 per share. On November 11, 2022, the Company elected to pay the fee with 933,334 shares of its common stock. The Company recorded the value of the agreement using the closing price of the Company’s common stock on November 11, 2022, and will amortize the expense over twelve months beginning in August 2022. At April 30, 2023, the balance of related party prepaid expenses was $247,000.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Apr. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	10. COMMITMENTS AND CONTINGENCIES Contractual Obligations On July 2, 2018, the Company entered into two Standard Exclusive License Agreements with Sublicensing Terms for AL001 with the Licensor and its affiliate, the University of South Florida (the “AL001 Licenses”), pursuant to which the Licensor granted the Company a royalty bearing exclusive worldwide licenses limited to the field of Alzheimer’s, under United States Patent Nos. (i) 9,840,521, entitled “Organic Anion Lithium Ionic Cocrystal Compounds and Compositions”, filed September 24, 2015 and granted December 12, 2017, and (ii) 9,603,869, entitled “Lithium Co-Crystals for Treatment of Neuropsychiatric Disorders”, filed May 21, 2016 and granted March 28, 2017. On February 1, 2019, the Company entered into the First Amendments to the AL001 Licenses, on March 30, 2021, the Company entered into the Second Amendments to the AL001 Licenses and on June 8, 2023, the Company entered into the Third Amendments to the AL001 Licenses (collectively, the “AL001 License Agreements”). The AL001 License Agreements require that the Company pay combined royalty payments of 4.5% The Company has already paid an initial license fee of $ 200,000 2,227,923 40,000 80,000 100,000 On May 1, 2016, the Company entered into a Standard Exclusive License Agreement with Sublicensing Terms for ALZN002 with the Licensor (the “ALZN002 License”), pursuant to which the Licensor granted the Company a royalty bearing exclusive worldwide license limited to the field of Alzheimer’s Immunotherapy and Diagnostics, under United States Patent No. 8,188,046, entitled “Amyloid Beta Peptides and Methods of Use”, filed April 7, 2009 and granted May 29, 2012. On August 18, 2017, the Company entered into the First Amendment to the ALZN002 License, on May 7, 2018, the Company entered into the Second Amendment to the ALZN002 License, on January 31, 2019, the Company entered into the Third Amendment to the ALZN002 License, on January 24, 2020, the Company entered into the Fourth Amendment to the ALZN002 License, on March 30, 2021, the Company entered into the Fifth Amendment to the ALZN002 License and on April 17, 2023, the Company entered into the Sixth Amendment to the ALZN002 License (collectively, the “ALZN002 License Agreement”). The ALZN002 License Agreement requires the Company to pay royalty payments of 4% The Company has already paid an initial license fee of $ 200,000 3,601,809 20,000 40,000 50,000 On November 19, 2019, the Company entered into two Standard Exclusive License Agreements with Sublicensing Terms for two additional indications of AL001 with the Licensor (the “November AL001 License”), pursuant to which the Licensor granted the Company a royalty bearing exclusive worldwide licenses limited to the fields of (i) neurodegenerative diseases excluding Alzheimer’s and (ii) psychiatric diseases and disorders. On March 30, 2021, the Company entered into the First Amendments to the November AL001 License and on April 17, 2023, the Company entered into the Second Amendments to the November AL001 License (collectively, the “November AL001 License Agreements”). The November AL001 License Agreements require the Company to pay royalty payments of 3% The Company paid an initial license fee of $ 20,000 40,000 80,000 100,000 These license agreements have an indefinite term that continue until the later of the date no licensed patent under the applicable agreement remains a pending application or enforceable patent, the end date of any period of market exclusivity granted by a governmental regulatory body, or the date on which the Company’s obligations to pay royalties expire under the applicable license agreement. Under the various license agreements, if the Company fails to meet a milestone by its specified date, Licensor may terminate the license agreement. The Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company while the Licensor remains the owner of any equity securities of the Company. Additionally, the Company is required to pay milestone payments on the due dates to the Licensor for the license of the AL001 technologies and for the ALZN002 technology, as follows: Original AL001 Licenses: Schedule of contractual obligation, fiscal year maturity Payment Due Date Event $ 50,000 * Completed September 2019 Pre-IND meeting $ 65,000 * Completed June 2021 IND application filing $ 190,000 * Completed December 2021 Upon first dosing of patient in a clinical trial $ 500,000 * Completed March 2022 Upon Completion of first clinical trial $ 1,250,000 24 months from completion of first Phase II clinical trial Upon first patient treated in a Phase III clinical trial $ 10,000,000 8 years from the effective date of the agreement Upon FDA approval * Milestone met and completed ALZN002 License: Payment Due Date Event $ 50,000 * Completed January 2022 Upon IND application filing $ 50,000 September 2023 Upon first dosing of patient in first Phase I clinical trial $ 500,000 24 months from completion of first Phase I clinical trial Upon completion of first Phase II clinical trial $ 1,000,000 12 months from completion of the first Phase II clinical trial Upon first patient treated in a Phase III clinical trial $ 10,000,000 7 years from the effective date of the agreement Upon FDA BLA approval * Milestone met and completed Additional AL001 Licenses: Payment Due Date Event $ 2,000,000 36 months from completion of the first Phase II clinical trial Upon first patient treated in a Phase III clinical trial $ 16,000,000 August 1, 2029 First commercial sale

EQUITY TRANSACTIONS

EQUITY TRANSACTIONS	12 Months Ended
	Apr. 30, 2023
Equity [Abstract]
EQUITY TRANSACTIONS	11. EQUITY TRANSACTIONS The Company is authorized to issue 10,000,000 0.0001 1,360,000 none 8,640,000 Common Stock On April 30, 2019, the Company and ALSF entered into a securities purchase agreement for the purchase of 10,000,000 15,000,000 1.50 5,000,000 5 3.00 15,000,000 12 In March 2021, the Company entered into the SPA with AL pursuant to which the Company agreed to sell an aggregate of 6,666,667 10 1.50 4 1.8 50,000 2,666,667 AL (i) purchased an additional 1,333,333 shares of common stock upon approval by the FDA of the Company’s IND for its Phase IA clinical trials for AL001 for a purchase price of $2 million; and (ii) purchased 2,666,667 shares of Common Stock upon the completion of these Phase IA clinical trials for AL001 for a purchase price of $4 million. In addition, the Company issued AL warrants to purchase an aggregate of 3,333,333 shares of common stock at an exercise price of $3.00 per share. Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, AL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $ 10 On June 17, 2021, the Company sold an aggregate of 2,875,000 375,000 5.00 14.4 12.9 2,000,000 10 5.00 In November 2022, the Company entered into a marketing and brand development agreement with AULT, effective August 1, 2022, whereby AULT will provide various marketing services over twelve months valued at $1.4 million. The Company had the right to pay the fee in cash or shares of its common stock with a value of $1.50 per share. On November 11, 2022, the Company elected to pay the fee with 933,334 shares of its common stock. The Company recorded the value of the agreement using the closing price of the Company’s common stock on November 11, 2022, and is amortizing the expense over twelve months beginning in August 2022. At April 30, 2023, the balance of related party prepaid expenses was $247,000.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Apr. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS The Company has evaluated subsequent events through the date the financial statements were issued. The Company has determined that there are no such events that warrant disclosure or recognition in the financial statements presented herein.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Apr. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”).
Accounting Estimates	Accounting Estimates The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include research and development, stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of April 30, 2023 and 2022, the Company had no
Fair Value of Financial Instruments	Fair Value of Financial Instruments Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase common stock. The fair values of warrants issued in connection with equity or debt issuance are determined using the Black-Scholes valuation model, a “Level 3” fair value measurement, based on the estimated fair value of the underlying common stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants and the risk free interest rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the warrants’ contractual life.
Income Taxes	Income Taxes The Company determines its income taxes under the asset and liability method. Under the asset and liability approach, deferred income tax assets and liabilities are calculated and recorded based upon the future tax consequences of temporary differences by applying enacted statutory tax rates applicable to future periods for differences between the financial statements carrying amounts and the tax basis of existing assets and liabilities. Generally, deferred income taxes are classified as current or non-current in accordance with the classification of the related asset or liability. Those not related to an asset or a liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are provided for significant deferred income tax assets when it is more likely than not that some or all of the deferred tax assets will not be realized. As of April 30, 2023, the Company had fully reserved the net deferred income tax assets by taking a full valuation allowance against these assets. The Company recognizes tax liabilities by prescribing a minimum probability threshold that a tax position must meet before a financial statement benefit is recognized and also provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The minimum threshold is defined as a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. To the extent that the final tax outcome of these matters is different than the amount recorded, such differences impact income tax expense in the period in which such determination is made. Interest and penalties, if any, related to accrued liabilities for potential tax assessments are included in income tax expense. U.S. GAAP also requires management to evaluate tax positions taken by the Company and recognize a liability if the Company has taken uncertain tax positions that more likely than not would not be sustained upon examination by applicable taxing authorities. Management of the Company has evaluated tax positions taken by the Company and has concluded that as of April 30, 2023, there were no uncertain tax positions taken, or expected to be taken, that would require recognition of a liability that would require disclosure in the financial statements.
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid to clinical research organizations that conduct certain research and development activities on behalf of the Company. The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire licenses, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and accounts for forfeitures as they occur. The Company’s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the satisfaction of the performance conditions as of the reporting date. The Company recognizes stock-based compensation expense for restricted stock on a straight-line basis over the requisite service period and accounts for forfeitures as they occur. The Company’s stock-based compensation for restricted stock is based upon the estimated fair value of the Company’s common stock on the date of grant. The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally requires significant judgment. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, the Company’s stock-based compensation could be materially different.
Warrants	Warrants The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging , During the year ended April 30, 2023, based on the terms of the Company’s warrant agreements, the Company accounted for the warrants as equity instruments as the warrants were indexed to the common stock, required settlement in shares and would be classified as equity under ASC 815.
Loss per Common Share	Loss per Common Share The Company utilizes FASB ASC Topic No. 260, Earnings per Share Since the effects of outstanding options, restricted stock units and warrants are anti-dilutive in the periods presented, shares of common stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of common stock underlying outstanding options and warrants that have been excluded from the computation of loss per common share: Schedule of antidilutive securities excluded from computation of earnings per share For the Year Ended April 30, 2023 2022 Stock options (1) 18,158,329 18,600,000 Restricted stock units 50,000 75,000 Warrants 10,149,788 10,149,788 28,358,117 28,824,788 (1) The Company has excluded 1,500,000 and 2,000,000 stock options for the years ended April 30, 2023 and 2022, respectively, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Apr. 30, 2023
Accounting Policies [Abstract]
Schedule of antidilutive securities excluded from computation of earnings per share	Schedule of antidilutive securities excluded from computation of earnings per share For the Year Ended April 30, 2023 2022 Stock options (1) 18,158,329 18,600,000 Restricted stock units 50,000 75,000 Warrants 10,149,788 10,149,788 28,358,117 28,824,788 (1) The Company has excluded 1,500,000 and 2,000,000 stock options for the years ended April 30, 2023 and 2022, respectively, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Apr. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of prepaid expenses and other current assets	Schedule of prepaid expenses and other current assets April 30, 2023 April 30, 2022 Prepaid clinical trial fees $ 352,635 $ - Prepaid insurance 92,154 155,880 Other prepaid expenses 2,800 7,176 Prepaid consulting fees - 186,667 Total prepaid expenses and other current assets $ 447,589 $ 349,723

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Apr. 30, 2023
Income Tax Disclosure [Abstract]
Schedule of Income before income tax, domestic and foreign	Schedule of Income before income tax, domestic and foreign April 30, 2023 April 30, 2022 Pre-tax loss: Federal $ (14,878,167 ) $ (12,362,059 ) Foreign - - Total pre-tax loss $ (14,878,167 ) $ (12,362,059 )
Schedule of deferred tax assets and liabilities	Schedule of deferred tax assets and liabilities April 30, 2023 April 30, 2022 Deferred income tax asset: Accruals $ 241,500 $ - Capitalized research expenditures 1,426,779 - Net operating loss carryover 6,885,428 8,376,539 Stock compensation 2,276,109 1,722,003 Total deferred tax asset 10,829,816 10,098,542 Fixed assets (16,767 ) (21,611 ) Valuation allowance (10,813,049 ) (10,076,931 ) Deferred income tax asset, net of allowance $ - $ -
Schedule of effective income tax rate reconciliation	Schedule of effective income tax rate reconciliation 2023 2022 Tax benefit at U.S. Federal statutory tax rate 21.0 % 21.0 % State income tax, net of federal benefit -18.3 % 12.3 % Increase (decrease) in tax rate resulting from: Change in valuation allowance -4.8 % -46.3 % Stock compensation 0.3 % 13.0 % Other 2.0 % -0.0 % Effective tax rate 0.0 % 0.0 %

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Apr. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of share-based payment arrangement, option, activity	Schedule of share-based payment arrangement, option, activity Outstanding Options Shares Number of Weighted Weighted Aggregate Balance at April 30, 2022 8,800,000 15,700,000 $ 1.2154 6.10 $ 2,219,700 Options granted (2,000,000 ) 2,000,000 $ 1.1700 9.58 Options exercised - (500,000 ) $ 0.0004 Options cancelled/forfeited 2,391,671 (2,391,671 ) $ 1.3415 Balance at April 30, 2023 9,191,671 14,808,329 $ 1.2154 6.18 $ 819,900 Options vested and expected to vest at April 30, 2023 13,808,329 $ 1.2187 5.93 $ 819,900 Options exercisable at April 30, 2023 13,036,969 $ 1.1784 5.82 $ 995,400
Schedule of stock options granted to employees and consultants	Schedule of stock options granted to employees and consultants For the Year Ended April 30, 2023 2022 Expected term (in years) 6.25 6.25 Volatility 88.94% 88.94% Risk-free interest rate 3.89% 2.20% Dividend yield 0.0% 0.0%
Schedule of stock-based compensation	Schedule of stock-based compensation For the Year Ended April 30, 2023 2022 Research and development $ (42,589 ) $ 423,167 General and administrative 3,625,214 3,985,402 Total $ 3,582,625 $ 4,408,569

WARRANTS (Tables)

WARRANTS (Tables)	12 Months Ended
	Apr. 30, 2023
Warrants
Schedule of common stock warrants outstanding	Schedule of common stock warrants outstanding Outstanding Exercisable Weighted Average Weighted Weighted Remaining Average Average Exercise Number Contractual Exercise Number Exercise Price Outstanding Life (years) Price Exercisable Price $ 1.00 500,000 0.8 $ 1.00 500,000 $ 1.00 $ 1.75 161,342 1.5 $ 1.75 161,342 $ 1.75 $ 3.00 9,427,196 1.9 $ 3.00 9,427,196 $ 3.00 $ 6.25 61,250 3.1 $ 6.25 61,250 $ 6.25 $ 1.00 6.25 10,149,788 1.9 $ 2.90 10,149,788 $ 2.90
Schedule of assumptions used	Schedule of assumptions used For the year ended April 30, 2022 Expected term (in years) 5.00 Volatility 88.94% Risk-free interest rate 2.92% Dividend yield 0.0%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Apr. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of contractual obligation, fiscal year maturity	Schedule of contractual obligation, fiscal year maturity Payment Due Date Event $ 50,000 * Completed September 2019 Pre-IND meeting $ 65,000 * Completed June 2021 IND application filing $ 190,000 * Completed December 2021 Upon first dosing of patient in a clinical trial $ 500,000 * Completed March 2022 Upon Completion of first clinical trial $ 1,250,000 24 months from completion of first Phase II clinical trial Upon first patient treated in a Phase III clinical trial $ 10,000,000 8 years from the effective date of the agreement Upon FDA approval * Milestone met and completed ALZN002 License: Payment Due Date Event $ 50,000 * Completed January 2022 Upon IND application filing $ 50,000 September 2023 Upon first dosing of patient in first Phase I clinical trial $ 500,000 24 months from completion of first Phase I clinical trial Upon completion of first Phase II clinical trial $ 1,000,000 12 months from completion of the first Phase II clinical trial Upon first patient treated in a Phase III clinical trial $ 10,000,000 7 years from the effective date of the agreement Upon FDA BLA approval * Milestone met and completed Additional AL001 Licenses: Payment Due Date Event $ 2,000,000 36 months from completion of the first Phase II clinical trial Upon first patient treated in a Phase III clinical trial $ 16,000,000 August 1, 2029 First commercial sale

DESCRIPTION OF BUSINESS (Detail

DESCRIPTION OF BUSINESS (Details Narrative) - $ / shares	Apr. 30, 2023	Apr. 30, 2022
Accounting Policies [Abstract]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001

LIQUIDITY, GOING CONCERN AND _2

LIQUIDITY, GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended		14 Months Ended
	Mar. 31, 2021	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash		$ 5,100,000	$ 14,100,000	$ 14,100,000
Accumulated deficit		44,100,000	29,200,000	$ 29,200,000
Net loss		14,900,000
Cash used in operating activities		8,900,000
Value of common stock
Common stock par value		$ 0.0001	$ 0.0001	$ 0.0001
Subsidiaries [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of common stock	3,333,333
Common stock par value	$ 3
Securities Purchase Agreement [Member] | Subsidiaries [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of common stock				6,666,667
Value of common stock				$ 10,000,000
Common stock par value			$ 1.50	$ 1.50

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - shares		12 Months Ended
		Apr. 30, 2023	Apr. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		28,358,117	28,824,788
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	[1]	18,158,329	18,600,000
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		50,000	75,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		10,149,788	10,149,788
[1]The Company has excluded 1,500,000 and 2,000,000 stock options for the years ended April 30, 2023 and 2022, respectively, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Apr. 30, 2023	Apr. 30, 2022
Accounting Policies [Abstract]
Cash equivalents	$ 0	$ 0

NOTE RECEIVABLE, RELATED PART_2

NOTE RECEIVABLE, RELATED PARTY, NET (Details Narrative) - USD ($)		12 Months Ended
	Apr. 30, 2019	Apr. 30, 2023	Apr. 30, 2022
Defined Benefit Plan Disclosure [Line Items]
Number of shares purchase
Warrant terms		1 year 10 months 24 days
Outstanding receivable amount		$ 14,883,295	$ 14,883,295
Ault Life Sciences Fund LLC [Member] | Securities Purchase Agreement [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of shares purchase (in shares)	10,000,000
Number of shares purchase	$ 15,000,000
Shares purchase price, per share	$ 1.50
Ault Life Sciences Fund LLC [Member] | Securities Purchase Agreement [Member] | Warrant [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of warrants granted	5,000,000
Warrant terms	5 years
Exercise price (in dollars per share)	$ 3

PREPAID EXPENSES AND OTHER CU_3

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)	Apr. 30, 2023	Apr. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid clinical trial fees	$ 352,635
Prepaid insurance	92,154	155,880
Other prepaid expenses	2,800	7,176
Prepaid consulting fees		186,667
Total prepaid expenses and other current assets	$ 447,589	$ 349,723

PREPAID EXPENSES AND OTHER CU_4

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative) - USD ($)	Apr. 30, 2023	Jun. 16, 2022	Apr. 30, 2022
Prepaid clinical trial fees	$ 352,635
Purchase D&O Insurance		$ 492,000
ALZN002 License [Member]
Prepaid clinical trial fees	$ 936,000

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Pre-tax loss:
Federal	$ (14,878,167)	$ (12,362,059)
Foreign
Total pre-tax loss	$ (14,878,167)	$ (12,362,059)

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Apr. 30, 2023	Apr. 30, 2022
Deferred income tax asset:
Accruals	$ 241,500
Capitalized research expenditures	1,426,779
Net operating loss carryover	6,885,428	8,376,539
Stock compensation	2,276,109	1,722,003
Total deferred tax asset	10,829,816	10,098,542
Fixed assets	(16,767)	(21,611)
Valuation allowance	(10,813,049)	(10,076,931)
Deferred income tax asset, net of allowance

INCOME TAXES (Details 2)

INCOME TAXES (Details 2)	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Income Tax Disclosure [Abstract]
Tax benefit at U.S. Federal statutory tax rate	21%	21%
State income tax, net of federal benefit	(18.30%)	12.30%
Increase (decrease) in tax rate resulting from:
Change in valuation allowance	(4.80%)	(46.30%)
Stock compensation	0.30%	13%
Other	2%	(0.00%)
Effective tax rate	0%	0%

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Operating Loss Carryforwards [Line Items]
Valuation allowance	$ 10,813,049	$ 10,076,931
Uncertain tax positions	0
Interest or penalties	$ 0
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		32,787,753
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		$ 11,419,279

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details)	12 Months Ended
	Apr. 30, 2023 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Shares available for grant begining (in shares)	8,800,000
Number of shares begining (in shares)	15,700,000
Weighted average exercise price begining (in dollars per share) | $ / shares	$ 1.2154
Weighted average remaining contractual life begining (years)	6 years 1 month 6 days
Aggregate intrinsic value begining | $	$ 2,219,700
Shares available for grant, Options granted	(2,000,000)
Number of shares, Options granted | $ / shares	$ 2,000,000
Weighted average exercise price, Options granted | $ / shares	$ 1.1700
Weighted average remaining contractual life, Option granted (years)	9 years 6 months 29 days
Shares available for grant, Options exercised
Number of shares, Options exercised	(500,000)
Weighted average exercise price, Options exercised | $ / shares	$ 0.0004
Shares available for grant, Options cnacelled/forfieted	2,391,671
Number of shares, Options cancelled/forfeited	(2,391,671)
Weighted average exercise price, Options cancelled/forfeited | $ / shares	$ 1.3415
Shares available for grant end (in shares)	9,191,671
Number of shares end (in shares)	14,808,329
Weighted average exercise price end (in dollars per share) | $ / shares	$ 1.2154
Weighted average remaining contractual life end (years)	6 years 2 months 4 days
Aggregate intrinsic value end | $	$ 819,900
Number of shares, Options vested and expected to vest at end	13,808,329
Weighted average exercise price, Options vested and expected to vest at end | $ / shares	$ 1.2187
Weighted average remaining contractual life, Options vested and expected to vest at end	5 years 11 months 4 days
Aggregate intrinsic value, Options vested and expected to vest at end | $	$ 819,900
Number of shares, Options exercisable at end	13,036,969
Weighted average exercise price, Options exercisable at end | $ / shares	$ 1.1784
Weighted average remaining contractual life, Options exercisable at end	5 years 9 months 25 days
Aggregate intrinsic value, Options exercisable at end | $	$ 995,400

STOCK-BASED COMPENSATION (Det_2

STOCK-BASED COMPENSATION (Details 1) - Employees and Consultants [Member]	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (in years)	6 years 3 months	6 years 3 months
Volatility	88.94%	88.94%
Risk-free interest rate	3.89%	2.20%
Dividend yield	0%	0%

STOCK-BASED COMPENSATION (Det_3

STOCK-BASED COMPENSATION (Details 2) - USD ($)	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 3,582,625	$ 4,408,569
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	(42,589)	423,167
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 3,625,214	$ 3,985,402

STOCK-BASED COMPENSATION (Det_4

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)						12 Months Ended
	Oct. 14, 2021	Mar. 23, 2021	Nov. 26, 2019	Mar. 01, 2019	Apr. 30, 2016	Apr. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted						2,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number						$ 819,900
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term						5 years 11 months 4 days
Unamortized Stock Based Compensation [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number						$ 1,200,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term						1 year 7 months 6 days
Perfromance Contingent Stock Options [Member] | Key Employees and Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted		450,000	4,250,000
Terms of award			In the event any of the stock price milestones are not achieved within three years, the unvested portion of the performance options will be reduced by 25%.
Perfromance Contingent Stock Options [Member] | Two Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted	200,000
Stock Incentive Plan 2016 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares authorized for issuance					12,500,000
Additional number of shares available for issuance				7,500,000
Stock Incentive Plan 2016 [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiration period					10 years

WARRANTS (Details)

WARRANTS (Details)	Apr. 30, 2023 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number warrant outstanding | shares	10,149,788
Weighted average remaining contractual life (years)	1 year 10 months 24 days
Warrant outstanding, weighted average exercise price (in dollars per share)	$ 2.90
Number of warrant exercisable | shares	10,149,788
Warrant exercisable, weighted average exercise price (in dollars per share)	$ 2.90
Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercse price (in dollars per share)	1
Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercse price (in dollars per share)	6.25
1.00 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercse price (in dollars per share)	$ 1
Number warrant outstanding | shares	500,000
Weighted average remaining contractual life (years)	9 months 18 days
Warrant outstanding, weighted average exercise price (in dollars per share)	$ 1
Number of warrant exercisable | shares	500,000
Warrant exercisable, weighted average exercise price (in dollars per share)	$ 1
1.75 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercse price (in dollars per share)	$ 1.75
Number warrant outstanding | shares	161,342
Weighted average remaining contractual life (years)	1 year 6 months
Warrant outstanding, weighted average exercise price (in dollars per share)	$ 1.75
Number of warrant exercisable | shares	161,342
Warrant exercisable, weighted average exercise price (in dollars per share)	$ 1.75
3.00 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercse price (in dollars per share)	$ 3
Number warrant outstanding | shares	9,427,196
Weighted average remaining contractual life (years)	1 year 10 months 24 days
Warrant outstanding, weighted average exercise price (in dollars per share)	$ 3
Number of warrant exercisable | shares	9,427,196
Warrant exercisable, weighted average exercise price (in dollars per share)	$ 3
6.25 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercse price (in dollars per share)	$ 6.25
Number warrant outstanding | shares	61,250
Weighted average remaining contractual life (years)	3 years 1 month 6 days
Warrant outstanding, weighted average exercise price (in dollars per share)	$ 6.25
Number of warrant exercisable | shares	61,250
Warrant exercisable, weighted average exercise price (in dollars per share)	$ 6.25

WARRANTS (Details 1)

WARRANTS (Details 1) - Warrant [Member]	12 Months Ended
	Apr. 30, 2022 Number
Expected term (in years)	5 years
Measurement Input, Option Volatility [Member]
Warrants measurement input	88.94
Measurement Input, Risk Free Interest Rate [Member]
Warrants measurement input	2.92
Measurement Input, Expected Dividend Rate [Member]
Warrants measurement input	0

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)				12 Months Ended
	Mar. 28, 2022	Jul. 28, 2021	Jun. 17, 2021	Apr. 30, 2022
Warrant 2022 [Member]
Aggregate number of stock repurchase				2,000,000
Exercise price (in dollars per share)	$ 3	$ 3	$ 6.25	$ 3
Number of stock repurchase	1,333,333	666,667	61,250	61,250
Warrant 2022 [Member] | DPL [Member]
Exercise price (in dollars per share)	$ 1.50	$ 1.50
Number of stock repurchase	2,666,667	1,333,333
Amount of stock repurchase	$ 4,000,000	$ 2,000,000
Warrant [Member]
Exercise price (in dollars per share)				$ 6.25

OTHER RELATED PARTY TRANSACTI_2

OTHER RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended				12 Months Ended
	Apr. 26, 2022	Jun. 15, 2021	May 31, 2021	Mar. 31, 2021	Apr. 30, 2022
Mr. Horne [Member]
Related Party Transaction [Line Items]
Number of shares issued for services, value			$ 50,000
IPO [Member] | Mr. Ault [Member]
Related Party Transaction [Line Items]
Description of conversion			the effectiveness of the IPO, and in consideration for (i) the conversion of 750,000 shares of the Company’s Series A Preferred Shares beneficially owned by Mr. Ault through Ault Life Sciences, Inc. into 15,000,000 shares of common stock; (ii) the extension of the maturity date of the note in the original principal amount of $15,000,000 issued to the Company by ALSF, an entity controlled by Mr. Ault, to December 31, 2023; and (iii) the resignation by Mr. Ault as a director and executive officer of the Company
Percentage of outstanding common shares			5%
Consulting Agreement [Member] | IPO [Member] | Mr. Ault [Member]
Related Party Transaction [Line Items]
Advisory and consulting services fees			$ 50,000
Digital Power Lending [Member] | Securities Purchase Agreement [Member]
Related Party Transaction [Line Items]
Number of shares sold (in shares)		2,000,000		6,666,667
Value of stock issued	$ 4,000,000			$ 10,000,000
Description of milestones				In addition, the Company issued AL warrants to purchase an aggregate of 3,333,333 shares of common stock at an exercise price of $3.00 per share. Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million on April 26, 2022, AL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of the date of this Annual Report.
Share price (in dollar per shares)		$ 5
DPL [Member]
Related Party Transaction [Line Items]
Amount grant for consulting services					$ 88,000

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details)	12 Months Ended
	Apr. 30, 2023 USD ($)
Pre-IND Meeting [Member] | AL001 License [Member]
Product Liability Contingency [Line Items]
Payment	$ 50,000
Due date	Completed September 2019	[1],[2]
IND Application Filing [Member] | AL001 License [Member]
Product Liability Contingency [Line Items]
Payment	$ 65,000
Due date	Completed June 2021	[1],[2]
Upon First Dosing of Patient in Clinical Trial [Member] | AL001 License [Member]
Product Liability Contingency [Line Items]
Payment	$ 190,000
Due date	Completed December 2021	[1],[2]
Upon Completion of First Clinical Trial [Member] | AL001 License [Member]
Product Liability Contingency [Line Items]
Payment	$ 500,000
Due date	Completed March 2022	[1],[2]
Upon First Patient Treated In A Phase III Clinical [Member] | AL001 License [Member]
Product Liability Contingency [Line Items]
Payment	$ 1,250,000
Due date	24 months from completion of first Phase II clinical trial
Upon First Patient Treated In A Phase III Clinical [Member] | Additional AL001 License [Member]
Product Liability Contingency [Line Items]
Payment	$ 2,000,000
Due date	36 months from completion of the first Phase II clinical trial
Upon FDA Approval [Member] | AL001 License [Member]
Product Liability Contingency [Line Items]
Payment	$ 10,000,000
Due date	8 years from the effective date of the agreement
Upon IND Application Filing [Member] | ALZN002 License [Member]
Product Liability Contingency [Line Items]
Payment	$ 50,000
Due date	Completed January 2022	[1]
Upon First Dosing Of Patient In First Phase I Clinical Trial [Member] | ALZN002 License [Member]
Product Liability Contingency [Line Items]
Payment	$ 50,000
Due date	September 2023
Upon Completion Of First Phase II Clinical Trial [Member] | ALZN002 License [Member]
Product Liability Contingency [Line Items]
Payment	$ 500,000
Due date	24 months from completion of first Phase I clinical trial
Upon First Patient Treated In Phase III Clinical Trial [Member] | ALZN002 License [Member]
Product Liability Contingency [Line Items]
Payment	$ 1,000,000
Due date	12 months from completion of the first Phase II clinical trial
Upon FDA BLA Approval [Member] | ALZN002 License [Member]
Product Liability Contingency [Line Items]
Payment	$ 10,000,000
Due date	7 years from the effective date of the agreement
First Commercial Sale [Member] | Additional AL001 License [Member]
Product Liability Contingency [Line Items]
Payment	$ 16,000,000
Due date	August 1, 2029
[1]Milestone met and completed [2]Milestone met and completed

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)			1 Months Ended
	Jul. 02, 2018	May 02, 2016	Nov. 19, 2019
AL001 License [Member]
Product Liability Contingency [Line Items]
Percentage of royalty payments on net sales of product	4.50%
Description of licenses agreements	The Company has already paid an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of the AL001 technologies, the Licensor received 2,227,923 shares of the Company’s common stock. Minimum royalties for AL001 License Agreements are $40,000 on the first anniversary of the first commercial sale, $80,000 on the second anniversary first commercial sale and $100,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the AL001 License Agreements.
Initial license fees	$ 200,000
Number of common stock shares received	2,227,923
AL001 License [Member] | First Anniversary [Member]
Product Liability Contingency [Line Items]
Payments for royalties	$ 40,000
AL001 License [Member] | Second Anniversary [Member]
Product Liability Contingency [Line Items]
Payments for royalties	80,000
AL001 License [Member] | Third Anniversary [Member]
Product Liability Contingency [Line Items]
Payments for royalties	$ 100,000
ALZN002 License [Member]
Product Liability Contingency [Line Items]
Percentage of royalty payments on net sales of product		4%
Description of licenses agreements		The Company has already paid an initial license fee of $200,000 for ALZN002. As an additional licensing fee for the license of ALZN002, the Licensor received 3,601,809 shares of the Company’s common stock. Minimum royalties for ALZN002 are $20,000 on the first anniversary of the first commercial sale, $40,000 on the second anniversary first commercial sale and $50,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the ALZN002 License Agreement.
Initial license fees		$ 200,000
Number of common stock shares received		3,601,809
ALZN002 License [Member] | First Anniversary [Member]
Product Liability Contingency [Line Items]
Payments for royalties		$ 20,000
ALZN002 License [Member] | Second Anniversary [Member]
Product Liability Contingency [Line Items]
Payments for royalties		40,000
ALZN002 License [Member] | Third Anniversary [Member]
Product Liability Contingency [Line Items]
Payments for royalties		$ 50,000
Additional AL001 License [Member]
Product Liability Contingency [Line Items]
Percentage of royalty payments on net sales of product			3%
Description of licenses agreements			The Company paid an initial license fee of $20,000 for the additional indications. Minimum royalties for November AL001 License Agreements are $40,000 on the first anniversary of the first commercial sale, $80,000 on the second anniversary first commercial sale and $100,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the November AL001 License Agreements.
Initial license fees			$ 20,000
Additional AL001 License [Member] | First Anniversary [Member]
Product Liability Contingency [Line Items]
Payments for royalties			40,000
Additional AL001 License [Member] | Second Anniversary [Member]
Product Liability Contingency [Line Items]
Payments for royalties			80,000
Additional AL001 License [Member] | Third Anniversary [Member]
Product Liability Contingency [Line Items]
Payments for royalties			$ 100,000

EQUITY TRANSACTIONS (Details Na

EQUITY TRANSACTIONS (Details Narrative) - USD ($)			1 Months Ended
	Mar. 09, 2021	Apr. 30, 2019	Jun. 17, 2021	Mar. 31, 2021	Apr. 30, 2023	Apr. 30, 2022
Class of Stock [Line Items]
Preferred stock, shares authorized					10,000,000	10,000,000
Preferred stock, par value (in dollars per share)					$ 0.0001	$ 0.0001
Warrant terms					1 year 10 months 24 days
Proceeds from sale of equity			$ 2,875,000
Offering price			$ 5
Gross proceeds			$ 14,400,000
Underwriting discounts,commissions and offering expenses			12,900,000
Underwriter's [Member]
Class of Stock [Line Items]
Proceeds from sale of equity			$ 375,000
Warrant [Member]
Class of Stock [Line Items]
Exercise price (in dollars per share)						6.25
ALSF [Member]
Class of Stock [Line Items]
Shares purchase price		$ 15,000,000
Warrant terms		12 months
AL [Member]
Class of Stock [Line Items]
Number of shares purchase			2,000,000
Shares purchase price			$ 10,000,000
Shares purchase price (in dollars per share)			$ 5
Securities Purchase Agreements [Member] | ALSF [Member]
Class of Stock [Line Items]
Number of shares purchase		10,000,000
Shares purchase price		$ 15,000,000
Shares purchase price (in dollars per share)		$ 1.50
Securities Purchase Agreements [Member] | ALSF [Member] | Warrant [Member]
Class of Stock [Line Items]
Number of shares purchase		5,000,000
Warrant terms		5 years
Exercise price (in dollars per share)		$ 3
Securities Purchase Agreements [Member] | Digital Power Lending [Member]
Class of Stock [Line Items]
Number of shares issued				6,666,667
Proceeds from sale of equity				$ 10,000,000
Shares issued price per share				$ 1.50
Proceeds from related party	$ 4,000,000
Advance from related parties	$ 1,800,000
Description of purchase agreement terms				AL (i) purchased an additional 1,333,333 shares of common stock upon approval by the FDA of the Company’s IND for its Phase IA clinical trials for AL001 for a purchase price of $2 million; and (ii) purchased 2,666,667 shares of Common Stock upon the completion of these Phase IA clinical trials for AL001 for a purchase price of $4 million. In addition, the Company issued AL warrants to purchase an aggregate of 3,333,333 shares of common stock at an exercise price of $3.00 per share.
Securities Purchase Agreements [Member] | Digital Power Lending [Member] | Final Tranche [Member]
Class of Stock [Line Items]
Additional right to invest				$ 10,000,000
Securities Purchase Agreements [Member] | Ault Global [Member] | Convertible Promissory Note [Member]
Class of Stock [Line Items]
Number of shares issued	2,666,667
Shares value surrender for cancellation	$ 50,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					8,640,000
Preferred stock, par value (in dollars per share)					$ 0.0001	$ 0.0001
Preferred stock shares designated					1,360,000	1,360,000
Preferred stock, shares issued					0	0
Preferred stock, shares outstanding					0	0